Posts in Career miniseries
How to navigate the jump from academia to a career in biotechnology: lessons from one scientist to another

It has been a bumpy ride for RNA interference-based therapeutics. The protein-silencing phenomenon that shot into the spotlight with its 2006 Nobel Prize fell (aptly) quiet thereafter, suffering clinical disappointments and losing high-profile backing. But it is back with a bang: the first RNAi drug was FDA approved in August and a number of Big Pharma companies are striking deals with developers. Does this mark a watershed moment for RNAi therapeutics?

Read More